Kirin Holdings’ LC-Plasma Study: A Potential Game-Changer in Immune Health
Kirin Holdings Company, Limited ((KNBWY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Kirin Holdings Company, Limited is collaborating with RDC Clinical Pty Ltd on a study titled ‘The Effects of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Disease in Australian Healthy Adults.’ This randomized, placebo-controlled, double-blind study aims to assess how LC-Plasma affects the immune system and its efficacy in reducing symptoms of upper respiratory infections in healthy adults.
Intervention/Treatment: The study tests the effects of a dietary supplement, LC-Plasma, which is taken as a 50mg tablet daily for four weeks. The aim is to enhance immune response and alleviate symptoms of respiratory infections, compared to a placebo.
Study Design: This Phase 3 clinical trial uses a randomized, parallel intervention model with quadruple masking. This means participants, care providers, investigators, and outcomes assessors are all blinded to the group assignments. The primary purpose is treatment-focused.
Study Timeline: The study began on February 17, 2025, with the latest update on June 18, 2025. These dates are crucial as they provide a timeline for recruitment and data collection, indicating the study’s current status and progress.
Market Implications: This study could significantly impact Kirin Holdings’ stock performance by potentially validating LC-Plasma as an effective immune-boosting supplement. Positive results may enhance investor confidence and position Kirin favorably against competitors in the health supplement industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.
